03-0207-00

SMC^® Human PD-1 High Sensitivity Immunoassay Kit

Used for ultrasensitive quantification of Human PD-1 in human serum and plasma

• Synonym(e): PD-1 Single Molecule Counting kit, PD-1 ultra-sensitive immunoassay, PD-1 immunoassay kit, Programmed cell death protein 1 kit, PD-1 kit
• NACRES: NA.47
• UNSPSC Code: 12161503
• Species reactivity: human
• Technique(s): single molecule counting: suitable
• Usage: kit sufficient for 96 wells
• Compatibility: for use with FemtoQuest^™ and SMCxPRO^® instruments

Eigenschaften

• Produktname: SMC^® Human PD-1 High Sensitivity Immunoassay Kit,
• Quality Segment: 200
• description: Used for ultrasensitive quantification of Human PD-1 in human serum and plasma
• product line: SMC^®
• usage: kit sufficient for 96 wells
• species reactivity: human
• parameter: 50 μL sample volume (diluted 2-fold in standard diluent)
• technique(s): single molecule counting: suitable
• input: serum; plasma (K2 EDTA)
• UniProt accession no.: Q15116
• compatibility: for use with FemtoQuest^™ and SMCxPRO^® instruments
• shipped in: wet ice
• storage temp.: 2-8°C

Beschreibung

General description

Programmed cell death protein 1 (PD-1), CD279, is a type I membrane protein found in T cells, B cells, and macrophages that binds Programmed cell death ligand 1 and 2 (PD-L1 and PD-L2). PD-1 is found in both soluble and insoluble forms. PD-1 regulates the body’s immune response through a variety of pathways, down-regulating immune system activity and suppressing T-cell inflammatory activity. PD-1 has been implicated as playing a role in cancers, autoimmune diseases, the immune response to viruses, and in immunological pathways related to brain repair. As an immune checkpoint, PD-1 promotes apoptosis of antigen-specific T-cells in lymph nodes and reduces apoptosis in regulatory T-cells. Blockers of the PD-1 pathway have been approved as cancer therapeutics.

Application

Immuno-Oncology

Features and Benefits

• Next-Gen Sensitivity For Low-Expression Targets: Designed to quantify PD-1 even in samples with minimal immune checkpoint activity.
• Illuminate Immune Exhaustion: Quantify PD-1 expression on CD8+ T cells to study T-cell exhaustion in cancer and chronic infections.
• Advance Immuno-Oncology Research: Track soluble PD-1 as a biomarker of immune suppression, tumor progression, or therapeutic response.
• Support Autoimmune and Viral Studies: Investigate PD-1’s role in immune regulation, IL-10 induction, and CD4+ T-cell inhibition.

Packaging

96 well assay

Analysis Note

• Sensitivity: LLOQ 3,470 fg/mL* (SMCxPRO^® Instrument)
• Standard Curve Range: 870-3,000,000 fg/mL
• Intra-assay CV: <15%
• Inter-assay CV: <20%
• Linearity: Serum: 107% Plasma: 83%
• Recovery: Serum: 93% Plasma 83%

*Indicative LLOQ created from average of 14 independent in house runs, where >80% met same value defined with CV & Recovery +/- 20%. Refer to CoA for lot specific performance.

Other Notes

Although PD-1 was detectable in rat, mouse, monkey, and canine samples, the assay has not been verified for these species.

Legal Information

FEMTOQUEST is a trademark of Merck KGaA, Darmstadt, Germany

SMC is a registered trademark of Singulex

SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sicherheitshinweise

• Piktogramme: GHS08,GHS07
• Signalwort: Danger
• Zielorgane: Respiratory Tract
• Lagerklasse: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Was ist los?: WGK 3
• Gefahrencodes: H302 + H312 + H332,H319,H360FD,H373,H412,EUH430
• Sicherheitshinweise: P201 - P202 - P273 - P308 + P313 - P391 - P405 - P501
• Hazard Classifications: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - ED ENV 1 - Eye Irrit. 2 - Repr. 1B - STOT RE 2 Inhalation